Using the Body’s Immune
System to Fight Cancer

CancerVAX, Inc. is developing immunotherapy cancer treatments that use the body’s immune system to fight cancer

Much like COVID-19 vaccines that train the body to recognize and destroy the coronavirus, we are developing cancer vaccines that train the body to target and destroy cancer cells. Our immuno- therapy platform is aimed at creating lower cost personalized CAR T-cell therapies as well as generalized antibody treatments through nanotechnology and gene editing innovations.

Our initial drug development is targeted at treating Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. There is currently no FDA approved treatment to prevent recurrence.

Our research is performed at the UCLA Jonsson Comprehensive Cancer Center by a leading cancer research team. We believe the resulting immunotherapy platform will be able to target other cancers such as adrenal cancer and brain cancer, as well as enabling the development of other vaccines and drugs.

Latest News

CancerVAX Announces Research Program

CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced that it has entered into a sponsored research agreement with UCLA...

CancerVAX Closes Series A Funding Round

CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced it has closed its $2 million series A funding round...

CancerVAX Launched

CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced the formation of the Company by Lindsay Mann, an experienced healthcare executive...

CancerVAX Announces Research Program

CancerVAX Closes Series A Funding Round

CancerVAX Launched

CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced that it has entered into a sponsored research agreement with UCLA...

CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced it has closed its $2 million series A funding round...

CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced the formation of the Company by Lindsay Mann, an experienced healthcare executive...